Liver Diseases News - LARVOL Sigma

Liver Diseases	Welcome, Profile Billing Logout

«1 2...85 86 87 88 899091 92 93 94 95...98 99 »

||||||||||  candesartan cilexetil / Generic mfg.
Enrollment change:  Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C (clinicaltrials.gov) -  Apr 22, 2012
P2, N=0, Withdrawn,  Sponsor: Kaiser Permanente
N=50 --> 0

||||||||||  propranolol / Generic mfg.
Trial termination:  Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding (clinicaltrials.gov) -  Apr 19, 2012
P3, N=120, Terminated,  Sponsor: University of Padova
N=50 --> 0 Recruiting --> Terminated; From the interim analysis resulted that more than 1000 patients were required to demonstrate a significant difference between the 2 treatments.

|||||||||| Enrollment closed: Effect of Dietary Macronutrient Composition (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=24, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Terminated; From the interim analysis resulted that more than 1000 patients were required to demonstrate a significant difference between the 2 treatments. Recruiting --> Active, not recruiting

||||||||||  Veldona (Interferon α lozenge) / Hayashibara, Otsuka, Amarillo
Trial completion, Combination therapy:  Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C (clinicaltrials.gov) -  Apr 19, 2012
P2, N=169, Completed,  Sponsor: Amarillo Biosciences, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  mitomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Combination therapy, Surgery:  Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) -  Apr 19, 2012
P1, N=11, Active, not recruiting,  Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed N=30 --> 11

|||||||||| New P3 trial: A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection (clinicaltrials.gov) - Apr 18, 2012
P3, N=795, Terminated, Sponsor: Johnson & Johnson Medical, China

|||||||||| New P3 trial: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (clinicaltrials.gov) - Apr 18, 2012
P3, N=725, Active, not recruiting, Sponsor: Bristol-Myers Squibb

||||||||||  TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P2 trial:  Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) -  Apr 18, 2012
P2, N=58, Recruiting,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute

||||||||||  Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
New P2 trial, Combination therapy:  VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C (clinicaltrials.gov) -  Apr 18, 2012
P2, N=64, Completed,  Sponsor: Vertex Pharmaceuticals Incorporated

||||||||||  TMC647055 / J&J, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1 trial, Combination therapy:  Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir (clinicaltrials.gov) -  Apr 18, 2012
P1, N=7, Completed,  Sponsor: Janssen R&D Ireland

||||||||||  prednisone / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial withdrawal:  Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients (clinicaltrials.gov) -  Apr 17, 2012
P=N/A, N=0, Withdrawn,  Sponsor: Maimonides Medical Center
N=30 --> 11 Active, not recruiting --> Withdrawn

||||||||||  prednisone / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change:  Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients (clinicaltrials.gov) -  Apr 17, 2012
P=N/A, N=0, Withdrawn,  Sponsor: Maimonides Medical Center
Active, not recruiting --> Withdrawn N=40 --> 0

||||||||||  valacyclovir / Generic mfg.
New P2 trial:  Herpes Simplex Type 1 Suppression in Hepatitis C (clinicaltrials.gov) -  Apr 17, 2012
P2, N=25, Recruiting,  Sponsor: Department of Veterans Affairs

|||||||||| Trial completion: QUANTUM-1: The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency (clinicaltrials.gov) - Apr 17, 2012
P=N/A, N=49, Completed, Sponsor: Medical University of South Carolina
N=40 --> 0 Active, not recruiting --> Completed

||||||||||  faldaprevir (BI201335) / Boehringer Ingelheim
New P1 trial:  Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment (clinicaltrials.gov) -  Apr 17, 2012
P1, N=32, Completed,  Sponsor: Boehringer Ingelheim Pharmaceuticals

||||||||||  RG4929 / Roche
Trial completion:  A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) -  Apr 17, 2012
P1, N=82, Completed,  Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
Trial completion:  A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B (clinicaltrials.gov) -  Apr 17, 2012
P4, N=200, Completed,  Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial withdrawal, Surgery: Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant (clinicaltrials.gov) - Apr 16, 2012
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Suspended --> Withdrawn

|||||||||| Enrollment change, Surgery: Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant (clinicaltrials.gov) - Apr 16, 2012
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
Suspended --> Withdrawn N=25 --> 0

||||||||||  Ocaliva (obeticholic acid) / Intercept
Enrollment change:  Study of INT-747 in Patients With Diabetes and Presumed NAFLD (clinicaltrials.gov) -  Apr 16, 2012
P2, N=64, Completed,  Sponsor: Intercept Pharmaceuticals
N=25 --> 0 N=45 --> 64

||||||||||  entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
New P3 trial:  Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine (clinicaltrials.gov) -  Apr 16, 2012
P3, N=180, Recruiting,  Sponsor: Seoul National University Hospital

||||||||||  faldaprevir (BI201335) / Boehringer Ingelheim
New P3 trial, Combination therapy:  Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial (clinicaltrials.gov) -  Apr 16, 2012
P3, N=131, Completed,  Sponsor: Boehringer Ingelheim Pharmaceuticals

||||||||||  Myrbetriq (mirabegron) / Astellas
New P1 trial:  A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects (clinicaltrials.gov) -  Apr 16, 2012
P1, N=32, Completed,  Sponsor: Astellas Pharma Europe BV

|||||||||| New P2 trial, Combination therapy: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment (clinicaltrials.gov) - Apr 15, 2012
P2, N=0, Withdrawn, Sponsor: Hoffmann-La Roche

|||||||||| New P2 trial, Preclinical: Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis (clinicaltrials.gov) - Apr 14, 2012
P2, N=60, Recruiting, Sponsor: Stempeutics Research Pvt Ltd

|||||||||| New P1 trial, Monotherapy: A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers (clinicaltrials.gov) - Apr 12, 2012
P1, N=18, Completed, Sponsor: GlaxoSmithKline

||||||||||  Besivo (besifovir) / Gilead, LG Chem, Ildong
Trial completion:  Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B (clinicaltrials.gov) -  Apr 12, 2012
P2b, N=115, Completed,  Sponsor: LG Life Sciences
N=45 --> 64 Active, not recruiting --> Completed

||||||||||  Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Biomarker:  GENUPI: Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir (clinicaltrials.gov) -  Apr 11, 2012
P=N/A, N=73, Recruiting,  Sponsor: Association HGE CHU Bordeaux Sud

||||||||||  Xalkori (crizotinib) / Pfizer
New P1 trial, Metastases:  Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients (clinicaltrials.gov) -  Apr 10, 2012
P1, N=70, Recruiting,  Sponsor: Pfizer

||||||||||  ficlatuzumab (AV-299) / LG Chem
Trial completion, Metastases:  A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (clinicaltrials.gov) -  Apr 10, 2012
P1, N=19, Completed,  Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P4 trial: PRIGA: Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis (clinicaltrials.gov) - Apr 9, 2012
P4, N=70, Recruiting, Sponsor: Sara Varea

||||||||||  patupilone (EPO 906) / Novartis
Enrollment change, Monotherapy, Metastases:  Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma (clinicaltrials.gov) -  Apr 8, 2012
P2, N=25, Completed,  Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=65 --> 25

|||||||||| New P2 trial: Intraoperative Dialysis in Liver Transplantation (clinicaltrials.gov) - Apr 8, 2012
P2, N=50, Recruiting, Sponsor: University of Alberta

|||||||||| Trial completion: endtxninHE: S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE (clinicaltrials.gov) - Apr 8, 2012
P=N/A, N=60, Completed, Sponsor: Govind Ballabh Pant Hospital
N=65 --> 25 Recruiting --> Completed

||||||||||  Campath (alemtuzumab) / Sanofi
Trial withdrawal:  Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) -  Apr 8, 2012
P1, N=0, Withdrawn,  Sponsor: Richard Burt, MD
Recruiting --> Completed Recruiting --> Withdrawn

||||||||||  Campath (alemtuzumab) / Sanofi
Enrollment change:  Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) -  Apr 8, 2012
P1, N=0, Withdrawn,  Sponsor: Richard Burt, MD
Recruiting --> Withdrawn N=10 --> 0

|||||||||| Clinical: Seroepidemiologic Study of Spermatozoal Transmission of Hepatitis B Virus (HBV) (clinicaltrials.gov) - Apr 7, 2012
P=N/A, N=407, Completed, Sponsor: YiYang Zhu

|||||||||| New P3 trial: Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (clinicaltrials.gov) - Apr 5, 2012
P3, N=390, Active, not recruiting, Sponsor: Bristol-Myers Squibb

|||||||||| Enrollment closed, Surgery: Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC (clinicaltrials.gov) - Apr 4, 2012
P4, N=100, Active, not recruiting, Sponsor: Kyoto University
N=10 --> 0 Recruiting --> Active, not recruiting

||||||||||  Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial:  An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (clinicaltrials.gov) -  Apr 3, 2012
P3, N=74, Active, not recruiting,  Sponsor: Janssen-Cilag International NV

|||||||||| New P2 trial: Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D (clinicaltrials.gov) - Apr 2, 2012
P2, N=60, Recruiting, Sponsor: University of Zurich

||||||||||  faldaprevir (BI201335) / Boehringer Ingelheim
New P1 trial:  Drug-drug Interaction of BI 201335 and Microgynon (clinicaltrials.gov) -  Apr 2, 2012
P1, N=16, Completed,  Sponsor: Boehringer Ingelheim Pharmaceuticals

|||||||||| New P3 trial: Coffee Effect in HCV-related Hepatitis (clinicaltrials.gov) - Apr 1, 2012
P3, N=40, Completed, Sponsor: Azienda Ospedaliera di Padova

||||||||||  ribavirin / Generic mfg.
Enrollment closed, Combination therapy:  GS-7977 With Ribavirin for Hepatitis C (SPARE) (clinicaltrials.gov) -  Mar 30, 2012
P1/2, N=79, Active, not recruiting,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  beclabuvir (BMS-791325) / BMS, Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Trial initiation date, Combination therapy:  Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications (clinicaltrials.gov) -  Mar 29, 2012
P2, N=316, Active, not recruiting,  Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Initiation date: Mar 1945 --> Nov 2011

||||||||||  Daklinza (daclatasvir) / BMS
Trial initiation date, Combination therapy:  Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care (clinicaltrials.gov) -  Mar 29, 2012
P2, N=208, Completed,  Sponsor: Bristol-Myers Squibb
Initiation date: Mar 1945 --> Nov 2011 Initiation date: Feb 2011 --> Jun 2011

||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases:  Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Mar 29, 2012
P2, N=33, Completed,  Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Feb 2011 --> Jun 2011 N=25 --> 33

||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases:  Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) -  Mar 29, 2012
P2, N=33, Completed,  Sponsor: UNC Lineberger Comprehensive Cancer Center
N=25 --> 33 Active, not recruiting --> Completed

||||||||||  Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy:  RESTORE: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Na (clinicaltrials.gov) -  Mar 28, 2012
P3, N=107, Completed,  Sponsor: Janssen R&D Ireland

||||||||||  Januvia (sitagliptin) / Merck (MSD)
New P1 trial, Combination therapy:  A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients (clinicaltrials.gov) -  Mar 28, 2012
P1, N=3, Terminated,  Sponsor: Institut National de la Sant



	Diseases Companies Products Productz Mechanisms of Action Sites